津药药业
(600488)
| 流通市值：46.19亿 | | | 总市值：46.19亿 |
| 流通股本：10.92亿 | | | 总股本：10.92亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,231,536,127.33 | 1,588,375,382.25 | 785,765,994.13 | 3,215,285,232.59 |
| 营业收入 | 2,231,536,127.33 | 1,588,375,382.25 | 785,765,994.13 | 3,215,285,232.59 |
| 二、营业总成本 | 2,012,848,166.08 | 1,394,545,207.57 | 693,723,469.32 | 2,936,885,787.12 |
| 营业成本 | 1,321,933,224.74 | 925,881,252.74 | 465,071,873.83 | 1,754,090,289.96 |
| 税金及附加 | 27,498,095.97 | 17,800,755.33 | 9,164,114.59 | 39,788,190.75 |
| 销售费用 | 271,650,581.62 | 186,843,883.82 | 88,859,231.04 | 569,973,577.12 |
| 管理费用 | 292,866,221.78 | 195,666,882.43 | 90,833,119.51 | 360,608,288.94 |
| 研发费用 | 90,347,424.39 | 63,172,029.25 | 37,752,655.26 | 204,492,012.31 |
| 财务费用 | 8,552,617.58 | 5,180,404 | 2,042,475.09 | 7,933,428.04 |
| 其中:利息费用 | 15,263,768.23 | 10,225,504.54 | 5,146,270.47 | 28,816,379.9 |
| 其中:利息收入 | 8,359,081.66 | 5,048,520.03 | 2,571,093.3 | 8,123,858.11 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 869,606.64 | 2,465,706.88 | -608,206.44 | -9,091,758.55 |
| 资产处置收益 | 404,023.42 | -9,235.51 | -9,235.51 | -33,485.38 |
| 资产减值损失(新) | -43,243,167.66 | -42,225,004.75 | -17,987,733.97 | -72,186,782.86 |
| 信用减值损失(新) | -680,559.09 | -494,265.4 | -470,479.88 | -273,649.8 |
| 其他收益 | 20,375,694.56 | 14,732,677.22 | 6,451,221.42 | 28,740,388.69 |
| 四、营业利润 | 196,413,559.12 | 168,300,053.12 | 79,418,090.43 | 225,554,157.57 |
| 加:营业外收入 | 1,263,485.68 | 1,087,218.63 | 218,442.88 | 1,852,145.79 |
| 减:营业外支出 | 69,507,142.15 | 69,219,369.58 | 18,782.61 | 893,212.81 |
| 五、利润总额 | 128,169,902.65 | 100,167,902.17 | 79,617,750.7 | 226,513,090.55 |
| 减:所得税费用 | 15,872,766.68 | 15,790,547.92 | 4,157,578 | 18,300,542.36 |
| 六、净利润 | 112,297,135.97 | 84,377,354.25 | 75,460,172.7 | 208,212,548.19 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 112,297,135.97 | 84,377,354.25 | 75,460,172.7 | 208,212,548.19 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 69,539,855.74 | 49,304,239.41 | 58,050,125.92 | 133,450,642.68 |
| 少数股东损益 | 42,757,280.23 | 35,073,114.84 | 17,410,046.78 | 74,761,905.51 |
| 扣除非经常损益后的净利润 | 135,710,827.84 | 116,604,760.71 | 57,329,593.9 | 136,288,020.42 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.06 | 0.05 | 0.05 | 0.12 |
| (二)稀释每股收益 | 0.06 | 0.05 | 0.05 | 0.12 |
| 八、其他综合收益 | 1,112,670.76 | 1,263,521.32 | 446,865.49 | 61,586,860.24 |
| 归属于母公司股东的其他综合收益 | 1,112,670.76 | 1,263,521.32 | 446,865.49 | 61,586,860.24 |
| 九、综合收益总额 | 113,409,806.73 | 85,640,875.57 | 75,907,038.19 | 269,799,408.43 |
| 归属于母公司股东的综合收益总额 | 70,652,526.5 | 50,567,760.73 | 58,496,991.41 | 195,037,502.92 |
| 归属于少数股东的综合收益总额 | 42,757,280.23 | 35,073,114.84 | 17,410,046.78 | 74,761,905.51 |
| 公告日期 | 2025-10-29 | 2025-08-23 | 2025-04-29 | 2025-03-27 |
| 审计意见(境内) | | | | 标准无保留意见 |